HONG KONG - Mumbai-based Glenmark Pharmaceuticals Ltd. has been granted manufacturing and marketing approval for the launch of its antiviral drug, favipiravir, for the treatment of mild to moderate COVID-19, a move it deems a “landmark development for COVID-19 patients in India.”
A second attempt by Nabriva Therapeutics plc to win U.S. approval for the antibiotic Contepo (fosfomycin) has been undone by COVID-19. Manufacturing issues stymied the original NDA. This time, restrictions of FDA staff travel to Europe sunk the venture, leading to a new complete response letter (CRL) for the candidate as a potential treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis.
PARIS – Stilla Technologies SAS, of Villejuif, France, is supplying a new, cost-effective approach for COVID-19 testing by combining its digital polymerase chain reaction (PCR) technology with the group testing method. “This approach greatly increases testing capacity and meets the highest quality standards,” Rémi Dangla, co-founder and CEO of Stilla Technologies, told BioWorld.
COLOMBIA – The COVID-19 pandemic has put Latin America’s biotech sector under extreme pressure and highlighted flaws in the ecosystem throughout the region, not the least of which is a lack of viable networks to facilitate cooperation.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Anpac Bio, Beijing Yuan Jian Health Management, Koru Medical Systems, Masimo, Pixium, Seizure Tracker, Tuberous Sclerosis Alliance.
RSS
